

SCIENTIFIC REPORTS



OPEN

Ndrg1 promotes adipocyte differentiation and sustains their function

Kai Cai, Rabih El-Merahbi, Mona Loeffler, Alexander E. Mayer & Grzegorz Sumara

Adipocytes play a central role in maintaining metabolic homeostasis in the body. Differentiation of adipocyte precursor cells requires the transcriptional activity of peroxisome proliferator-activated receptor- γ (Ppar γ) and CCAAT/enhancer binding proteins (C/EBPs). Transcriptional activity is regulated by signaling modules activated by a plethora of hormones and nutrients. Mechanistic target of rapamycin complexes (mTORC) 1 and 2 are central for the coordination of hormonal and nutritional inputs in cells and are essential for adipogenesis. Serum glucocorticoid kinase 1 (Sgk1)-dependent phosphorylation of N-Myc downstream-regulated gene 1 (NdrG1) is a hallmark of mTORC2 activation in cells. Moreover, Ppar γ activation promotes NdrG1 expression. However, the impact of NdrG1 on adipocyte differentiation and function has not yet been defined. Here, we show that NdrG1 expression and its Sgk1-dependent phosphorylation are induced during adipogenesis. Consistently, we demonstrate that NdrG1 promotes adipocyte differentiation and function by inducing Ppar γ expression. Additionally, our results indicate that NdrG1 is required for C/EBP α phosphorylation. Moreover, we found that NdrG1 phosphorylation by Sgk1 promotes adipocyte formation. Taken together, we show that induction of NdrG1 expression by Ppar γ and its phosphorylation by Sgk1 kinase are required for the acquisition of adipocyte characteristics by precursor cells.

White adipocytes are central for the regulation of lipid and metabolic homeostasis¹. Importantly, both deficits in adipose tissue development (lipodystrophy) and the excessive accumulation of adipose tissue result in metabolic disorders, including type 2 diabetes². Differentiation of mesenchymal precursor cells into adipocytes is crucial for adipose tissue acquisition². The terminal differentiation of adipocytes requires the coordinated expression of genes regulating their specific functions. Peroxisome proliferator-activated receptor- γ (Ppar γ) and CCAAT/enhancer binding proteins (C/EBPs) are major transcription factors promoting the acquisition of molecular adipocyte characteristics by precursor cells². A plethora of extracellular signals, including hormones and nutrients, activate intracellular signaling cascades that modulate Ppar γ , C/EBPs and other transcription factors to regulate adipogenesis³.

Mechanistic target of rapamycin (mTOR) activity is dependent on both hormones (insulin) and nutrients levels⁴. In cells, mTOR kinase is present in two large multi-component signaling complexes; mTORC1 and mTORC2 (mTOR complex 1 and 2). mTORC1 is defined primarily by raptor protein, while mTORC2 by the presence of the rictor subunit. Depletion of raptor specifically abrogates the activity of mTORC1, while rictor is specifically required for mTORC2 function⁴. Genetic and pharmacological studies revealed that both mTORC1 and mTORC2 are required for adipogenesis and promote adipocyte function^{5–8}. Yet, the function of distal mTORC effectors in the regulation of adipocyte formation is not completely understood.

mTORC2 activates Sgk1, which is required for adipocyte formation^{9–12}. NdrG1 is a major phosphorylation target of Sgk1^{13–15}. Moreover, expression of NdrG1 in adipocytes seems to be promoted by Ppar γ ^{16, 17}. NdrG1 was previously implicated in regulation of progression of multiple tumors^{18–22}, peripheral neuropathy^{23, 24}, T cell energy²⁵, as well as bone remodeling and macrophage differentiation²⁶. Additionally, a number of studies suggest that NdrG1 might regulate other signaling cascades that influence adipocyte differentiation. This includes the Wnt/ β -Catenin cascade, glycogen synthase kinase 3 β (Gsk3 β), as well as extracellular regulated kinase 1/2 (Erk1/2)^{3, 27–29}. However, the impact of NdrG1 on the regulation of adipogenesis and adipocyte function has not been elucidated. Here, we show that NdrG1 promotes adipogenesis and sustains adipocyte function by promoting

Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Josef-Schneider-Str. 2, Haus D15, D-97080, Würzburg, Germany. Correspondence and requests for materials should be addressed to G.S. (email: grzegorz.sumara@uni-wuerzburg.de)




Figure 1. NdrG1 promotes adipocyte differentiation and lipolysis. (A) Expression of NdrG1 mRNA in 3t311 cells at different stages of differentiation with or without rosiglitazone (Rosi). Stars indicate significance between expression levels in control and Rosi-treated cells at the specific time points ($*P < 0.05$, $**P < 0.01$, $***P < 0.001$ according to a t-test). (B) Total and phospho-NdrG1 levels at different stages of 3t311 differentiation. (C) NdrG1 protein levels in cells targeted by different shRNAs against NdrG1 (NdrG1 sh). (D) Relative TG content and (E) neutral lipid staining (OilRedO) on differentiated 3t311 cells after knockdown of NdrG1. (F) Lipogenesis rate in control and NdrG1 sh cells, unstimulated (unstim.) or upon insulin (Ins.) stimulation. (G) Relative glycerol and (H) FFA levels in medium from differentiated 3t311 control cells or NdrG1 knockdown cells stimulated with control medium or isoproterenol (Iso). For all graphs, each data point represents a biological replicate. Stars indicate significance for given parameters between control and NdrG1-depleted cells. ($*P < 0.05$, $**P < 0.01$, $***P < 0.001$ according to ANOVA followed by the Post hoc Tukey test).

Ppar γ expression and possibly C/Ebp α activity. Moreover, our results suggest that Sgk1-dependent phosphorylation of threonine 346 on NdrG1 promotes adipocyte differentiation.

Results

NdrG1 is induced during adipocyte differentiation. To test whether NdrG1 could regulate adipocyte differentiation, we first measured its expression in the 3t311 pre-adipocyte cell line, which was subjected to an adipocyte-differentiation cocktail for different time points. Expression of NdrG1 mRNA increased progressively during differentiation, reaching more than 10-fold elevation in fully differentiated cells compared to undifferentiated 3t311 cells (Fig. 1A). Previous studies indicated that NdrG1 is a target of the master transcription factor promoting adipogenesis – Ppar γ ^{16,17}. In fact, 3t311 cells differentiated in the presence of the Ppar γ agonist rosiglitazone present markedly higher expression of NdrG1 after 8, 12 and 14 days of differentiation (Fig. 1A). Consistently, protein levels for NdrG1 also increased during 3t311 differentiation (Fig. 1B).

Upon mTORC2-dependent activation of Sgk1 kinase, Sgk1 phosphorylates NdrG1 at five residues (S300, T328, T346, T346 and T366)^{13–15}. Importantly, using a phospho-specific antibody, we found that the levels of NdrG1 phosphorylated by Sgk1 on T346 also increased during adipocyte differentiation (Fig. 1B). These results suggest that NdrG1 could play an important role in the regulation of adipocyte differentiation, function, or both.

NdrG1 is required for adipocyte differentiation. To assess the role of NdrG1 in adipocyte differentiation, we generated stable 3t311 cell lines expressing shRNA against NdrG1. Expression of shRNA sequence 3 and 4 against NdrG1 (NdrG1 sh3 and sh4) resulted in efficient knockdown of NdrG1 protein (Fig. 1C). Using AdipoRed-mediated triglyceride (TG) quantification and neutral lipid OilRedO staining, we demonstrated that knockdown of NdrG1 in 3t311 cells subjected to 14 days of adipogenic differentiation resulted in roughly 50% reduced lipid accumulation compared to control cells (Fig. 1D and E). Consistently, *de novo* lipid production (lipogenesis) was also markedly reduced in the absence of NdrG1 (Fig. 1F). Next, we tested whether NdrG1 deficiency also impacts other functions of adipocytes. To assess the release of TG stored in lipid droplets during




Figure 2. NdrG1 promotes Ppar γ expression and stability as well as C/Ebp α phosphorylation. **(A)** Relative mRNA levels for indicated genes in control and NdrG1-deficient differentiated 3t3l1 cells. (n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001 according to t-test). **(B)** Western blot for Ppar γ and Gapdh in control and NdrG1-depleted differentiated 3t3l1 cells stimulated with cycloheximide for indicated time points. Representative picture was chosen from three biological replicates. **(C)** Quantification of relative amount of Ppar γ in cells treated with cycloheximide in relation to the initial (without treatment) levels of Ppar γ in respective control and NdrG1-depleted cells (n = 3, * P < 0.05, ** P < 0.01 according to t-test). **(D)** Relative TG content in control and NdrG1 sh 3t3l1 cells subjected to adipocyte differentiation cocktail with rosiglitazone (Rosi) or troglitazone (Tro). Each data point represents a biological replicate. Stars indicate significance for given parameters between control and NdrG1-depleted cells. (* P < 0.05, ** P < 0.01, *** P < 0.001 according to ANOVA followed by the Post hoc Tukey test). **(E)** Western blot analysis using indicated antibodies in control and NdrG1-deficient cells stimulated with insulin (Ins.) for the indicated time.

the process of lipolysis, we measured the levels of glycerol and free fatty acids (FFAs) released to the cell culture medium from differentiated 3t3l1 cells. Lipolysis was markedly reduced in the absence of NdrG1 (Fig. 1G and H). Indicating that also adipocytes function is affected by depletion of NdrG1.

NdrG1 promotes the expression of Ppar γ and phosphorylation of C/Ebp α . Next, we tested the expression levels of key transcription factors regulating adipocyte differentiation. mRNA levels of Ppar γ were markedly reduced in cells expressing shRNA against NdrG1 (Fig. 2A). Induction of C/Ebp α transcriptional activity is also required for proper adipocyte differentiation³, however depletion of NdrG1 did not influence C/Ebp α mRNA expression. Moreover, the levels of transcriptional targets of Ppar γ were reduced in cells depleted




Figure 3. Overexpression of NdrG1 promotes adipogenesis. (A) Western blot using indicated antibodies on extracts isolated from 3t3l1 control and FlagNdrG1-expressing cells. (B) Relative TG content and (C) neutral lipid staining (OilRedO) of differentiated 3t3l1 control and FlagNdrG1-expressing cells. (D) Relative mRNA levels for indicated genes in differentiated control and NdrG1-overexpressing 3t3l1 cells. (E) Relative glycerol and (F) FFA levels in medium from differentiated 3t3l1 control cells or NdrG1-overexpressing cells stimulated with control medium or Iso. Each data point represents a biological replicate (for bar plots $n = 3$). Stars indicate significance for given parameters between control and NdrG1-overexpressing cells. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ according to ANOVA followed by the Post hoc Tukey test).

from NdrG1 (Fig. 2A), including diacylglycerol acyltransferase (Dgat) as well as two crucial lipases promoting lipolysis, adipose triglyceride lipase (Atgl) and hormone sensitive lipase (Hsl)^{30–32}. Consistently, Ppar γ protein levels were markedly reduced in the absence of NdrG1 (Fig. 2B –without cycloheximide and Supplementary Fig. 1). To test if NdrG1 also regulates the stability of Ppar γ protein, we subjected NdrG1-deficient 3t3l1 cells to a cycloheximide chase experiment. Cycloheximide treatment resulted in a higher rate of disappearance of Ppar γ , in NdrG1-deficient cells, indicating that NdrG1 promotes Ppar γ stability (Fig. 2B and C). Next, we differentiated NdrG1-depleted and control 3t3l1 cells in the adipocyte differentiation cocktail supplemented with different concentrations of Ppar γ agonists (rosiglitazone, troglitazone). Both agonists markedly induced TG accumulation in 3t3l1 control and NdrG1-deficient cells. However, treatment with Ppar γ agonists did not fully abrogate the difference in TG content between control and NdrG1-deficient cells (Fig. 2D), suggesting that NdrG1 could additionally promote the differentiation of adipocytes by targeting other factors than Ppar γ .

Previous studies indicated that NdrG1 might regulate Gsk3 β and Erk1/2 activity, as well as the Wnt/ β -Catenin pathway²⁷. Gsk3 β and Erk1/2 have been shown to promote adipogenesis^{33, 34}, while expression of β -Catenin suppresses pre-adipocyte differentiation³⁵. We tested expression and activation of these proteins in cells depleted of NdrG1. Western blot analysis revealed that NdrG1 depletion does not influence the activation or levels of Erk1/2 (Fig. 2E and Supplementary Fig. 1). Similarly, levels of phosphorylated (inactive) and total Gsk3 β , as well as β -Catenin were not altered by NdrG1 silencing (Fig. 2E and Supplementary Fig. 1). Interestingly, Gsk3 β promotes phosphorylation of C/Ebp α on threonine 222/226³³. Therefore, we tested whether NdrG1 is required for C/Ebp α phosphorylation. We observed that depletion of NdrG1 suppresses basal and insulin stimulated phosphorylation of C/Ebp α on threonine 222/226, but does not influence total C/Ebp α protein levels (Fig. 2E).

These results suggest that NdrG1 promotes adipogenesis by enhancing Ppar γ expression. In addition, NdrG1 might also influence C/Ebp α activity through phosphorylation. However, the precise mechanisms of NdrG1 action needs to be determined.

Overexpression of NdrG1 promotes adipocyte differentiation. To determine if overexpression of NdrG1 is sufficient to enhance adipogenesis, we generated 3t3l1 cells ectopically expressing Flag-tagged NdrG1 (FlagNdrG1). Stable expression of FlagNdrG1 was confirmed by Western blotting (Fig. 3A). Overexpression of




Figure 4. Sgk1-dependent phosphorylation of Ndrgr1 is required for its pro-adipogenic function. **(A)** Western blot assessing the levels of expression of different FlagNdrgr1 phospho-mutant proteins using the indicated antibodies. **(B)** Relative TG content in differentiated 3t3l1 cells expressing the indicated phospho-mutants of Ndrgr1. Each data point represents an average TG content of individually generated and differentiated mixed stable cell populations of 3t3l1 cells expressing different Ndrgr1 mutants. (* $P < 0.05$ according to ANOVA followed by the Post hoc Tukey test).

Ndrgr1 resulted in an over two-fold elevation in the levels of TG in differentiated 3t3l1 cells compared to control cells (Fig. 3B and C). On the molecular level, overexpression of Ndrgr1 lead to elevated levels of markers defining adipocyte function. Specifically, we observed increased expression of Ppar γ , Dgat, stearoyl-CoA-desaturase (Scd1), acetyl-CoA carboxylase (Acc1), Atgl, Hsl, monoglyceride lipase (Mgl), adiponectin and leptin (Fig. 3D). Moreover, Ndrgr1 overexpression enhanced adipocyte function as indicated by increased lipolytic activity (Fig. 3E and F). Altogether, these data suggest that Ndrgr1 overexpression promotes adipogenesis and adipocyte function.

Sgk1-dependent phosphorylation of Ndrgr1 on T346 is required for adipogenesis. As a downstream effector of mTORC2, Sgk1 phosphorylates Ndrgr1 on multiple sites (S300, T328, T346, T356 and T366)^{13–15}. Previous studies indicated that Sgk1 is required for adipocyte differentiation¹¹. To test if Sgk1-dependent phosphorylation of Ndrgr1 is required for its function, we generated Ndrgr1 alanine mutants that cannot be phosphorylated at the respective residues and expressed them in 3t3l1 cells. Western blot analysis confirmed that all mutants were equally overexpressed as the control wild type form of Ndrgr1 (Fig. 4A). Next, we subjected all the cell lines to an adipogenic differentiation protocol. As expected, overexpression of the wild type form of Ndrgr1 resulted in markedly elevated TG accumulation compared to cells expressing empty vector (Fig. 4B). Overexpression of S300A, T328A, T356A and T366A mutants also resulted in a marked increase in TG accumulation in cells, comparable to wild-type overexpression (Fig. 4B). However, overexpression of the T346A mutant led to markedly lower TG accumulation than cells overexpressing the wild-type form of Ndrgr1 (Fig. 4B). These results indicate that Sgk1-dependent phosphorylation of Ndrgr1 on T346 promotes adipogenesis.

Ndrgr1 sustains adipocyte function after differentiation. To test if Ndrgr1 plays a role in the regulation of mature adipocyte function, we knocked down Ndrgr1 using transient siRNA transfection in fully differentiated 3t3l1 cells. Effective knockdown of Ndrgr1 was confirmed by Western blot (Fig. 5A). Consistent with our previous results, siRNA-mediated silencing of Ndrgr1 resulted in a reduced rate of lipogenesis (Fig. 5B). Moreover, knockdown of Ndrgr1 decreased the rate of isoproterenol-induced lipolysis in 3t3l1 cells, as indicated by a more than two-fold reduction in the concentration of FFAs and a more than three-times reduced levels of glycerol in the medium compared to control cells (Fig. 5C and D). To confirm these results, we knocked down Ndrgr1 in adipocytes differentiated from primary stromal vascular cells isolated from wild type mice. Ndrgr1 knockdown in primary cells resulted in a similarly reduced rate of lipolysis (Fig. 5E), demonstrating that the observed phenotype is not restricted to 3t3l1 cells.

Discussion

Our results indicate that Ndrgr1 is both activated during and required for adipogenesis. Moreover, in fully differentiated adipocytes Ndrgr1 stimulates lipolysis. Ndrgr1 promotes adipocyte formation partially by enhancing expression of the crucial pro-adipogenic transcription factor Ppar γ . However, Ndrgr1 might also regulate C/Ebpa adipogenic activity (Fig. 5F).

Ndrgr1 is a distal effector of mTORC2 activation in cells⁹. Disruption of mTORC signaling by silencing its component rictor results in reduced adipocyte differentiation⁶. Sgk1 kinase is directly activated by mTORC2; consistently, its depletion results in attenuated adipogenesis^{9–12}. In agreement with these data, we showed that Sgk1-dependent phosphorylation of Ndrgr1 is required for its pro-adipogenic function. However, previous results indicate that the mTORC2 signaling module suppresses lipolysis³⁶. As our results indicate that Ndrgr1 promotes lipolysis, mTORC2 must therefore suppress lipolysis by utilizing an Ndrgr1-independent mechanism. Of note, expression of Atgl and Hsl, which are targets of Ppar γ ^{31,32} were reduced in the absence of Ndrgr1. These results explain the attenuated lipolysis rate in the absence of Ndrgr1. Moreover, our results might indicate that defective lipolysis in cells deficient for Ndrgr1 may be a direct consequence of reduced differentiation of these cells. We showed that Ppar γ activation increases Ndrgr1 expression. On the other hand, our results indicate that Ndrgr1 promotes expression and stability of Ppar γ . Therefore we postulate that Ndrgr1 acts as a component of a positive feedback loop promoting Ppar γ action.




Figure 5. NdrG1 promotes lipolysis independent of its impact on adipocyte differentiation. (A) Western blot for the indicated proteins in differentiated 3T3L1 cells transfected with control or NdrG1 siRNA. (B) Lipogenesis rate in control siRNA and NdrG1 siRNA transfected cells (NdrG1 si), unstimulated (unstim.) or upon insulin (Ins.) stimulation. (C) Relative glycerol and (D) FFA levels in medium from differentiated 3T3L1 control cells or NdrG1 siRNA-treated cells stimulated with control medium or Iso. (E) Relative glycerol levels in adipocytes differentiated from primary stroma-vascular cells isolated from subcutaneous fat pads and transfected with non-targeted control (NTC) or NdrG1 siRNA. Each data point represents a biological replicate. Stars indicate significance for given parameters between control and NdrG1-depleted cells. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ according to ANOVA followed by the Post hoc Tukey test). (F) Model of NdrG1 action in adipocytes. mTORC2 activates Sgk1 kinase, which phosphorylates NdrG1 on T346. Phosphorylated NdrG1 increases expression of Ppar γ through an unknown mechanism to promote adipogenesis and adipocyte function. In a positive feedback loop, Ppar γ also promotes NdrG1 expression and stability. Additionally, NdrG1 promotes C/ebp α phosphorylation, which might influence its activity.

However, agonist-mediated activation of Ppar γ did not completely rescue the adipogenesis defect in NdrG1-deficient cells. This might be caused by the lower protein levels of Ppar γ in cells depleted of NdrG1. Alternatively, this might indicate that NdrG1 also regulates other components of the molecular machinery defining adipocyte differentiation. In fact, we observed that phosphorylation of C/ebp α on threonines 222/226 is markedly reduced in the absence of NdrG1. Threonines 222 and 226 on C/ebp α were originally identified as targets for Gsk3 β -dependent phosphorylation³³. However, a recent study indicated that C/ebp α is a poor substrate for Gsk3 β ³⁷. In fact, our results suggest that NdrG1 does not influence the total levels of Gsk3 β or its phosphorylated (inactive) form. This suggests that NdrG1 modulates C/ebp α phosphorylation by influencing Gsk3 β activity in another manner or by utilizing a Gsk3 β -independent mechanism. Also, the impact of C/ebp α T222/T226 phosphorylation on adipogenesis has not been directly assessed. Phosphorylation on these sites was originally proposed to enhance adipogenesis³³, but a recent study indicates that it might reduce C/ebp α activity³⁷.

Previous studies implicated NdrG1 in the regulation of Wnt/ β -Catenin as well as Erk1/2 action²⁷. Our results indicate that NdrG1 does not influence any of these pathways in adipocytes. Therefore, we postulate that NdrG1 primarily promotes adipogenesis by enhancing expression of Ppar γ . However, NdrG1 might also influence other adipogenic factors and the exact mechanism of its action needs to be defined further.

Methods

Pre-adipocyte culture and differentiation. 3T3L1 preadipocytes were cultured in DMEM supplemented with 10% fetal calf serum (FCS), and 40 μ g/ml Gentamicin at 37°C in a humidified atmosphere. For differentiation, 3T3L1 were grown to confluency. Two days post-confluency, the cells were switched to medium containing 10% fetal bovine serum, 1.5 μ g/ml insulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) and 1 μ M Dexamethasone (Dex) for 48 hours. This step was repeated for an additional 48 hours and then the induced cells were incubated with “Differentiation Medium” (DMEM supplemented with 10% FBS and 1.5 μ g/ml insulin) for up to 10 days to achieve differentiation to adipocytes. In the indicated experiments, Ppar γ agonists (rosiglitazone or troglitazone) were supplemented to the differentiation medium at indicated concentrations throughout the differentiation process. Fresh agonists were added to the medium every 48 h. All compounds were purchased from Sigma-Aldrich if not specified.

Stromal vascular cells (SVCs) containing pre-adipocytes were isolated from adipose tissue Briefly, subcutaneous white adipose tissue were collected from wild type BL6 mice and cut into small fragments with a scalpel. The sliced SVC fractions were treated with 2 mg/ml Collagenase D (Roche) in PBS containing 5 mM CaCl₂, 1% BSA

and P/S with shaking (300 rpm) at 37 °C for 40 minutes. After digestion of adipose tissue, the solution was filtered through a cell strainer with 45 µm pore size and centrifuged at 1250 rpm for 10 minutes to collect SVCs. SVCs were cultured in complete medium (DMEM/F12 containing 10% FBS, 1% sodium pyruvate (SP), 1% non-essential amino acids (NEAA) and P/S) until two days post-confluent and transferred into induction medium (DMEM/F12 containing 10% FBS, 1% SP, 1% NEAA and P/S, 0.2 µM Indomethacin, 0.5 µM Rosiglitazone, 0.5 mM IBMX and 1 µM Dex) for two times 48 hours. Then, the SVC cells were cultured into complete medium with 1.5 µg/mL insulin for up to 6 additional days.

siRNA transfection. Fully differentiated 3t3l1 cells were transfected using Dharmafect Duo transfection reagent with siRNA against NdrG1 or NonTarget control (Dharmacon) according to the manufacturer's protocol. Cells were used for experiments 48 hours post transfection.

Generation of stable knockdown and overexpression of wild type and mutant NdrG1. shRNA against NdrG1 was introduced into 3t3l1 cells using lentiviral particles. Specific shRNA sequences (available in Supplementary Table 1) were cloned in pGIPZ vector was described previously³⁸. The infected 3t3l1 cells were then selected by puromycin treatment (5 µg/ml). The pBabe-Puro vector was used for retrovirus-driven Flag-NdrG1 expression. A full length coding sequence of NdrG1 was introduced between EcoRI and BamHI restriction sites of this vector. Platinum-E (*Plat-E*) cell were utilized to produce retroviral particles. Infected 3t3l1 cells were selected with puromycin (5 µg/ml). NdrG1 mutants were generated using the site-directed mutagenesis kit from New England Biolabs according to the manufacturer's protocol.

Analyses of mRNA expression and protein levels. Quantitative polymerase chain reaction (qPCR) was performed using SYBR green Universal PCR master mix (Roche). mRNA was isolated using trizol reagent (Invitrogen). cDNA was generated using First Strand cDNA synthesis kit (Thermo Scientific). Primers used in this study are available in Supplementary Table 1. Western blot analyses were performed according to standard procedure. All antibodies were obtained from Cell Signaling Technology. For indicated experiments, cycloheximide (Sigma, 50 µg/ml concentration) was added to the culture medium to block protein translation. The levels of indicated proteins were assessed by western blot after the indicated time points.

Quantification of lipid levels and DNA content. Double staining of AdipoRed reagent (Lonza, Basel, Switzerland) and Hoechst 33342 (Invitrogen) was utilized to quantify the intracellular lipid accumulation in relation to DNA content. Oil-Red O staining (Sigma) was used to visualize TG in cells. To assay lipolysis, cells were starved for 2 hours in phenol red-free DMEM supplemented with 0.5% BSA, followed by stimulation with 10 µM isoproterenol (iso) (Sigma) for 2 hours in the same medium. FFAs in the medium were quantified using NEFA-reagent from Wako Chemicals and glycerol was quantified using the specific reagent from Sigma.

Lipogenesis assay. For determination of *de novo* lipogenesis, 3T3L1 cells were incubated with ³H-glucose (1 µCi/mL, Perkin Elmer) in the presence or absence of insulin for 3 h. Cells were washed twice with PBS and lysed in 0.1 N HCl. Lipids were then extracted with chloroform/methanol (2:1, v/v). The lipid-containing chloroform phase was used for liquid scintillation counting.

Statistical analysis. For multiple comparisons, one way analysis of variance (ANOVA) followed by the Post hoc Tukey test was used. For determination of significance between two experimental groups T-Test was used. Significance was accepted at the level of 0.05. Exact statistics are indicated for each figure.

References

- Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. *Cell* **156**, 20–44, doi:10.1016/j.cell.2013.12.012 (2014).
- Cristancho, A. G. & Lazar, M. A. Forming functional fat: a growing understanding of adipocyte differentiation. *Nat Rev Mol Cell Biol* **12**, 722–734, doi:10.1038/nrm3198 (2011).
- Lefterova, M. I. & Lazar, M. A. New developments in adipogenesis. *Trends Endocrinol Metab* **20**, 107–114, doi:10.1016/j.tem.2008.11.005 (2009).
- Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. *Cell* **149**, 274–293, doi:10.1016/j.cell.2012.03.017 (2012).
- Zhang, H. H. *et al.* Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. *PLoS One* **4**, e6189, doi:10.1371/journal.pone.0006189 (2009).
- Tang, Y. *et al.* Adipose tissue mTORC2 regulates ChREBP-driven *de novo* lipogenesis and hepatic glucose metabolism. *Nat Commun* **7**, 11365, doi:10.1038/ncomms11365 (2016).
- Yoon, M. S., Zhang, C., Sun, Y., Schoenherr, C. J. & Chen, J. Mechanistic target of rapamycin controls homeostasis of adipogenesis. *J Lipid Res* **54**, 2166–2173, doi:10.1194/jlr.M037705 (2013).
- Polak, P. *et al.* Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. *Cell Metab* **8**, 399–410, doi:10.1016/j.cmet.2008.09.003 (2008).
- Cybulski, N. & Hall, M. N. TOR complex 2: a signaling pathway of its own. *Trends Biochem Sci* **34**, 620–627, doi:10.1016/j.tibs.2009.09.004 (2009).
- Garcia-Martinez, J. M. & Alessi, D. R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *Biochem J* **416**, 375–385, doi:10.1042/BJ20081668 (2008).
- Di Pietro, N. *et al.* Serum- and glucocorticoid-inducible kinase 1 (SGK1) regulates adipocyte differentiation via forkhead box O1. *Mol Endocrinol* **24**, 370–380, doi:10.1210/me.2009-0265 (2010).
- Pearce, L. R., Sommer, E. M., Sakamoto, K., Wullschleger, S. & Alessi, D. R. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. *Biochem J* **436**, 169–179, doi:10.1042/BJ20102103 (2011).

13. Murakami, Y. *et al.* Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXc chemokine expression in human pancreatic cancer cells. *Biochem Biophys Res Commun* **396**, 376–381, doi:10.1016/j.bbrc.2010.04.100 (2010).
14. McCaig, C., Potter, L., Abramczyk, O. & Murray, J. T. Phosphorylation of NDRG1 is temporally and spatially controlled during the cell cycle. *Biochem Biophys Res Commun* **411**, 227–234, doi:10.1016/j.bbrc.2011.06.092 (2011).
15. Inglis, S. K. *et al.* SGK1 activity in Na⁺ absorbing airway epithelial cells monitored by assaying NDRG1-Thr346/356/366 phosphorylation. *Pflugers Arch* **457**, 1287–1301, doi:10.1007/s00424-008-0587-1 (2009).
16. Wang, H., Liu, L., Lin, J. Z., Aprahamian, T. R. & Farmer, S. R. Browning of White Adipose Tissue with Roscovitine Induces a Distinct Population of UCP1⁺ Adipocytes. *Cell Metab* **24**, 835–847, doi:10.1016/j.cmet.2016.10.005 (2016).
17. Wang, H., Qiang, L. & Farmer, S. R. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. *Mol Cell Biol* **28**, 188–200, doi:10.1128/MCB.00992-07 (2008).
18. Kovacevic, Z. *et al.* The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. *J Biol Chem* **291**, 1029–1052, doi:10.1074/jbc.M115.689653 (2016).
19. Sahni, S. *et al.* The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. *J Biol Chem* **289**, 9692–9709, doi:10.1074/jbc.M113.529511 (2014).
20. Fang, B. A. *et al.* Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. *Biochim Biophys Acta* **1845**, 1–19, doi:10.1016/j.bbcan.2013.11.002 (2014).
21. Stein, S. *et al.* NDRG1 is necessary for p53-dependent apoptosis. *J Biol Chem* **279**, 48930–48940, doi:10.1074/jbc.M400386200 (2004).
22. Murakami, Y. *et al.* N-myc downstream-regulated gene 1 promotes tumor inflammatory angiogenesis through JNK activation and autocrine loop of interleukin-1alpha by human gastric cancer cells. *J Biol Chem* **288**, 25025–25037, doi:10.1074/jbc.M113.472068 (2013).
23. Okuda, T. *et al.* NdrG1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves. *Mol Cell Biol* **24**, 3949–3956 (2004).
24. Echaniz-Laguna, A. *et al.* NDRG1-linked Charcot-Marie-Tooth disease (CMT4D) with central nervous system involvement. *Neuromuscul Disord* **17**, 163–168, doi:10.1016/j.nmd.2006.10.002 (2007).
25. Oh, Y. M. *et al.* NdrG1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2. *Nat Commun* **6**, 8698, doi:10.1038/ncomms9698 (2015).
26. Watari, K. *et al.* Impaired differentiation of macrophage lineage cells attenuates bone remodeling and inflammatory angiogenesis in NdrG1 deficient mice. *Sci Rep* **6**, 19470, doi:10.1038/srep19470 (2016).
27. Sun, J. *et al.* Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. *Carcinogenesis* **34**, 1943–1954, doi:10.1093/carcin/bgt163 (2013).
28. Wangpu, X. *et al.* The metastasis suppressor, NDRG1, inhibits “stemness” of colorectal cancer via down-regulation of nuclear beta-catenin and CD44. *Oncotarget* **6**, 33893–33911, doi:10.18632/oncotarget.5294 (2015).
29. Lu, W. J., Chua, M. S., Wei, W. & So, S. K. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3beta and Nur77 to prevent beta-catenin degradation. *Oncotarget* **6**, 29847–29859, doi:10.18632/oncotarget.4913 (2015).
30. Sugii, S. *et al.* PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. *Proc Natl Acad Sci USA* **106**, 22504–22509, doi:10.1073/pnas.0912487106 (2009).
31. Kershaw, E. E. *et al.* PPARgamma regulates adipose triglyceride lipase in adipocytes *in vitro* and *in vivo*. *Am J Physiol Endocrinol Metab* **293**, E1736–1745, doi:10.1152/ajpendo.00122.2007 (2007).
32. Deng, T. *et al.* Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. *Endocrinology* **147**, 875–884, doi:10.1210/en.2005-0623 (2006).
33. Ross, S. E., Erickson, R. L., Hemati, N. & MacDougald, O. A. Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. *Mol Cell Biol* **19**, 8433–8441 (1999).
34. Prusty, D., Park, B. H., Davis, K. E. & Farmer, S. R. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. *J Biol Chem* **277**, 46226–46232, doi:10.1074/jbc.M207776200 (2002).
35. Liu, J. & Farmer, S. R. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. *J Biol Chem* **279**, 45020–45027, doi:10.1074/jbc.M407050200 (2004).
36. Lamming, D. W. & Sabatini, D. M. A Central role for mTOR in lipid homeostasis. *Cell Metab* **18**, 465–469, doi:10.1016/j.cmet.2013.08.002 (2013).
37. Liu, H. K. *et al.* Functional characterisation of the regulation of CAAT enhancer binding protein alpha by GSK-3 phosphorylation of Threonines 222/226. *BMC Mol Biol* **7**, 14, doi:10.1186/1471-2199-7-14 (2006).
38. Fellmann, C. *et al.* An optimized microRNA backbone for effective single-copy RNAi. *Cell Rep* **5**, 1704–1713, doi:10.1016/j.celrep.2013.11.020 (2013).

Acknowledgements

We thank Dr. Ann Wehman, Dr. Olga Sumara and Jonathan Trujillo Viera for critical comments to our manuscript. This project was supported by Emmy Noether grant number Su 820/1-1 from the German Research Foundation. Mona Loeffler, Alexander F Mayer and Grzegorz Sumara are additionally supported by the European Research Council (ERC) Starting Grant SicMetabol.

Author Contributions

Kai Cai performed most of the experiments and contributed to experimental design. Rabih El-Merahbi and Alexander E. Mayer performed some experiments and contributed to experimental design. Mona Loeffler performed some experiments, contributed to experimental design and writing of the manuscript. Grzegorz Sumara was responsible for experimental design and wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-07497-x

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017